Home | NexPlasmaGen
15847
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-15847,bridge-core-2.6.4,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-24.9,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,qode-wpml-enabled,wpb-js-composer js-comp-ver-6.5.0,vc_responsive

FACTS

Breast Conserving Therapy (BCT)

 

Worldwide over 1 million women diagnosed with breast cancer undergo BCT (surgery with follow-up radiotherapy) annually as an alternative to mastectomy, whereby both procedures result in comparable survival rate for early breast cancer.

BCT Recurrence & Reoperation

 

The current standard of care recommending BCT suffers up to 15% recurrence rate within 10 years, and 20% reoperation rate within 90 days due to positive margin (residual cancer cells).

Breast Cancer Survival

 

5-years residual risks of recurrence for patients with stage I, II, III and IV cancers are about 7%, 11%, 13% and >20% respectively,  relating to 5-years survival rate of 100%, 93%, 72% and 22% respectively.

10

Number of peer-reviewed scientific papers

9

Number of projects completed

2

Number of patents and patent pending

27

Number of conferences

TEAM

Valérie Léveillé, Eng., M. Eng., PhD
CEO / Founder

Valérie has 14-yr experience in technology R&D, design and commercialization. She is co-inventor of NexPlasmaGen’s technology.

Audrey Glory, PhD
Preclinical trials leader

Audrey has 5-yr experience in conducting preclinical trials for breast and other cancers. She works at NexPlasmaGen and at the CR-CHUM.

Philip Wong, MDCM, MSc, FRCPC
Medical Advisor

Philip is an Assistant Professor at the Department of Radiation Oncology, University of Toronto. He is a clinician-investigator at the CR-CHUM. He leads NexPlasmaGen’s clinical program and is co-inventor of NexPlasmaGen’s technology.

Julie Lafontaine, PhD
Laboratory supervisor, CR-CHUM

Julie has 7-yr experience supervising Dr. Wong’s laboratory and plays a crucial role in NexPlasmaGen preclinical trials. She works at the CR-CHUM.

BOARD MEMBER

Valérie Léveillé, Eng., M. Eng., PhD
Board member and CEO

Valérie is currently the sole board member of NexPlasmaGen. New members will be added as we growth the company.

ADVISORS

At the moment, no advisory board has been formed. To come soon!

See our partners who support the company and our technology development

Supported in part by advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)

You met the team, now meet our technology!